Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab + Trastuzumab + mFOLFOX6 in HER2+ Gastric/Esophageal Cancer
NCT03783936Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in gastric adenocarcinoma and esophageal adenocarcinoma (EAC). Primary endpoint: Best Objective Response Rate at 24 weeks. Started Jan 2019; status: completed.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT03783936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783936.